MeiraGTx (MGTX) announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy, ESGCT, 2024 Annual Congress, ...
MeiraGTx is looking to march its Parkinson’s disease treatment forward into phase 3 after the gene therapy improved motor ...
The posters are available on the Posters and Publications page of the Company’s website.
According to MeiraGTx, AAV-GAD is designed to reprogramme dysfunctional circuits in the Parkinson's brain through the local ...
The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s ...
Exciting results for MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease, with promising phase 1/2 data and ...
MeiraGTx's clinical study of AAV-GAD for Parkinson's disease showed significant improvements in motor function and quality of ...
On Tuesday, MeiraGTx Holdings PLC (MGTX) stock saw a modest uptick, ending the day at $5.33 which represents a slight increase of $0.69 or 14.87% from the prior close of $4.64. The stock opened at $5.
MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 14.9% higher at $5.33. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...
Shares in MeiraGTx rose after the company said it received positive data in a clinical bridging study of AAV-GAD for the treatment of Parkinson's disease. Shares were up nearly 14% in premarket ...
US clinical-stage genetic meds company MeiraGTx Holdings has released positive top-line data from its clinical bridging study ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback